Investment Highlights
Key reasons to invest in Spoke Medical
£220M+ Market
Addressing a substantial and growing UK ear care market with 4 million annual procedures and clear international expansion potential.
Patented Innovation
First innovation in microsuction technology in over 50 years, with strong IP protection and regulatory approvals creating barriers to entry.
Clinical Validation
Independently validated by University of Salford Acoustics Calibration Laboratory, with compelling evidence of clinical benefits and safety improvements.
Recurring Revenue
Premium product with recurring revenue from consumables, creating a sustainable business model with strong margins and customer retention.
Regulatory Catalyst
ENT UK's 2024 clinical guidance on microsuction highlights significant risks with traditional equipment, creating an immediate market need for Zephyr's safer technology. This regulatory catalyst is driving accelerated adoption across all market segments.
Financial Projections
Our path to profitability
Key Financial Metrics
- Year 1 Revenue Target: £1.2M
- Year 3 Revenue Target: £5.8M
- Year 5 Revenue Target: £12.5M
- Gross Margin: 30-40%
- Projected Break-Even: Q4 2026
- Target EBITDA (Year 5): 22-25%
Use of Funds
- Sales & Marketing (40%): Expand UK sales team, develop marketing materials, implement demonstration program
- Manufacturing (25%): Scale production capacity, optimize supply chain, reduce COGS
- R&D (20%): Develop next-generation products, expand IP portfolio
- Regulatory & Compliance (10%): Obtain international approvals, maintain quality systems
- Working Capital (5%): Support inventory and accounts receivable growth
Leadership Team
Experienced professionals driving our success
Patrick Axon
Consultant ENT Surgeon with over 20 years of clinical experience. Former president of the British Society of Otology and advisor to ENT UK.
Neil Donnelly
Serial entrepreneur with a track record of building successful medical device companies. Previously founded and led MedTech innovations that achieved significant market penetration.
Sarah Chen, PhD
Biomedical engineer with expertise in medical device development and regulatory approval pathways. Previously led R&D teams at major medical technology companies.
James Wilson
Financial strategist with extensive experience in healthcare investment and MedTech scaling. Previously led successful funding rounds for multiple healthcare startups.
Advisory Board
- Professor David Thompson - Leading ENT specialist and researcher
- Dr. Elizabeth Chen - Former regulatory affairs director at major medical device company
- Michael Roberts - Healthcare investment specialist with 25+ years experience
- Dr. Samantha Patel - Audiology practice owner and clinical innovator
Investment Opportunity
A unique opportunity to participate in the next phase of growth
Current Funding Round
- Seeking: £2.5M in growth capital
- Use of Funds: Accelerate UK market penetration, prepare for European expansion
- Previous Funding: £1.2M seed round (2023)
- Current Valuation: Available upon request with signed NDA
- Minimum Investment: £100,000
Exit Strategy
- Primary Strategy: Strategic acquisition by established medical device company (5-7 year horizon)
- Secondary Strategy: Private equity investment for international expansion
- Comparable Exits: Recent medical device innovations in the ENT space have achieved 5-8x revenue multiples
Interested in Learning More?
Get in touch to discover how Zephyr is revolutionizing ear care.